Product details
Background:Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody.
• Cancer immunotherapy using checkpoint blockade., PMID:29567705
• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870
• Immune-related adverse events of checkpoint inhibitors., PMID:32382051
• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845
• Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113
• Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885
• Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160
• Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858
• Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360
• Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704






